Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Elizabeth Storrick"'
Autor:
Jennifer G. Le-Rademacher, Shauna Hillman, Elizabeth Storrick, Michelle R. Mahoney, Peter F. Thall, Aminah Jatoi, Sumithra J. Mandrekar
Publikováno v:
Cancers, Vol 12, Iss 11, p 3251 (2020)
This article introduces the adverse event (AE) burden score. The AE burden by treatment cycle is a weighted sum of all grades and AEs that the patient experienced in a cycle. The overall AE burden score is the total AE burden the patient experienced
Externí odkaz:
https://doaj.org/article/6cde63b1bfc649e2bc052a463d91986f
Publikováno v:
Journal of Cachexia, Sarcopenia and Muscle, Vol 10, Iss 6, Pp 1175-1182 (2019)
Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle
Longitudinal data serve an important role in understanding the cancer anorexia weight loss syndrome and in testing interventions to palliative and treat patients who develop this syndrome. The element of time and the interrelatedness of data points d
Autor:
Ellen K. Ritchie, Heidi D. Klepin, Elizabeth Storrick, Brittny Major, Jennifer Le-Rademacher, Martha Wadleigh, Alison Walker, Richard A. Larson, Gail J. Roboz
Publikováno v:
Blood advances. 6(12)
Geriatric assessment (GA) predicts survival among older adults with acute myeloid leukemia (AML) treated intensively. We evaluated the predictive utility of GA among older adults treated with low-intensity therapy on a multisite trial. We conducted a
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 3, Iss 2, Pp 176-182 (2019)
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Objectives To report the results of a survey conducted among Mayo Clinic medical oncologists, hematologists, and cancer prevention specialists to better understand the current practice of determining whether an adverse event that a patient experience
Autor:
Jonathan E. Kolitz, Susan M. Christner, Michaela Liedtke, Richard Stone, Geoffrey L. Uy, Meir Wetzler, Jan H. Beumer, Lionel D. Lewis, Jun Yin, Matthew J Wieduwilt, Wendy Stock, Elizabeth Storrick, Richard A. Larson, Steven M. Devine, Ryan J. Mattison, Bayard L. Powell
Publikováno v:
Blood Advances
Key Points Dasatinib and dexamethasone induction then allogeneic hematopoietic cell transplantation was feasible and effective for untreated Ph+ ALL.Treatment failure was associated with BCR-ABL1 T315I mutation, the p210 BCR-ABL1 isoform, or isolated
Autor:
Aminah Jatoi, Shauna Hillman, Peter F. Thall, Elizabeth Storrick, Sumithra J. Mandrekar, Michelle R. Mahoney, Jennifer Le-Rademacher
Publikováno v:
Cancers, Vol 12, Iss 3251, p 3251 (2020)
Cancers
Cancers; Volume 12; Issue 11; Pages: 3251
Cancers
Cancers; Volume 12; Issue 11; Pages: 3251
Simple Summary In cancer clinical trials, adverse event data are collected after every treatment cycle, using the Common Terminology Criteria for adverse events, which includes 837 terms. The vast number of potentially reportable adverse events over
Autor:
Megan Othus, Elizabeth Storrick, Brittny Major, Aminah Jatoi, Andrew S. Artz, Celalettin Ustun, Frederick R. Appelbaum, Krzysztof Mrózek, Larry D. Cripe, Such Nand, Brenda M. Sandmaier, Harry P. Erba, Selina Chow, Jacqueline M. Lafky, Gail J. Roboz, Geoffrey L. Uy, Jennifer Le-Rademacher, Zhuoxin Sun, Guido Marcucci, Mei-Jie Zhang, Thomas C. Shea, Martin S. Tallman, Mark R. Litzow, James M. Foran, Daniel J. Weisdorf, Clara D. Bloomfield, Eyal C. Attar, Richard A. Larson, Hai-Lin Wang, Richard Stone, Arti Hurria, Marcos de Lima
The preferred post-remission therapy for older patients with acute myeloid leukemia (AML) in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study, we compared the outcomes for older AML patients (age 60–77 year
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ace4ec2b994a8a3f0a33f558deb125e
https://europepmc.org/articles/PMC6842042/
https://europepmc.org/articles/PMC6842042/
Autor:
Zhuoxin Sun, Geoffrey L. Uy, Elizabeth Storrick, Sumithra J. Mandrekar, Frederick R. Appelbaum, Mark R. Litzow, Betsy LaPlant, Megan Othus, Guido Marcucci, Richard A. Larson, Hugo F. Fernandez, Richard Stone, Jun Yin
Publikováno v:
Blood. 132:1386-1386
Background: Overall survival (OS) remains the definitive primary efficacy endpoint to evaluate previously untreated acute myeloid leukemia (AML) therapies, but it requires prolonged follow-up. An earlier endpoint assessed post-treatment would expedit
Autor:
Mark R. Litzow, Thomas C. Shea, Mei-Jie Zhang, Eyal C. Attar, Arti Hurria, Hai-Lin Wang, Brittny Major, Marcos de Lima, Geoffrey L. Uy, Jennifer Le-Rademacher, Megan Othus, Richard Stone, Daniel J. Weisdorf, Clara D. Bloomfield, James M. Foran, Gail J. Roboz, Guido Marcucci, Elizabeth Storrick, Selina Chow, Aminah Jatoi, Larry D. Cripe, Celalettin Ustun, Harry P. Erba, Brenda M. Sandmaier, Jacqueline M. Lafky, Zhuoxin Sun, Richard A. Larson, Andrew S. Artz, Krzysztof Mrózek
Publikováno v:
Blood. 132:2170-2170
Introduction: The preferred post-remission therapy for older patients (pts) with AML remains uncertain. We compared outcomes for older AML pts in CR1 receiving HCT reported to the CIBMTR to older AML pts achieving CR1 on National Clinical Trials Netw
Autor:
Michaela Liedtke, Elizabeth Storrick, Scott E. Smith, Richard Stone, Jan H. Beumer, Meir Wetzler, Wendy Stock, Bayard L. Powell, Steven M. Devine, Jun Yin, Jonathan E. Kolitz, Ryan J. Mattison, Geoffrey L. Uy, Richard A. Larson, Matthew J. Wieduwilt
Publikováno v:
Blood. 132:309-309
Dasatinib with corticosteroid yields high complete remission (CR) rates in Ph+ ALL with minimal induction death. Optimal post-remission therapy is not known. We report a prospective study evaluating dasatinib/dexamethasone induction then consolidatio